Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

Tumor,Microenvironment,Concept,With,Cancer,Cells,,T-cells,,Nanoparticles,,Cancer,Associated

IO Biotech (NASDAQ:IOBT) on Monday released topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvanted).

The trial evaluated Cylembio in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.